Loading stock data…
BRKR
$36.79+0.08 (+0.22%)
Market ClosedLast close May 1
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bruker Corporation in the Healthcare sector is trading at $36.79. The stock is currently 35% below its 52-week high of $56.22, remaining 6.7% below its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why BRKR maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$36.79
Potential Upside
5%
Whystock Fair Value$38.63
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$46.79+27.2%
Range$35.00 – $60.00
Fundamentals
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BS...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.51B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.20
Div Yield
Strong income play. Yield provides a meaningful total return floor.
50.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.24%
Volume
Today's trading volume
1.36M
Recent News
Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard
A few weeks ago, a research paper out of MIT (the college) crossed my desk that most investors would have ignored.It was about worms. Specifically, it was about a team that had successfully mapped the entire brain of a microscopic worm — every neuron, every connection. Then it laid out what it would take to scale that process from a worm… to a mouse… and eventually, to a human.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now, here’s where things get interesting for us. For deca
3 Healthcare Stocks That Fall Short
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 5%.
Is Bruker (BRKR) Fairly Priced After Recent Short Term Share Price Rebound?
If you are wondering whether Bruker at around US$40 a share is a fair deal or not, you are in the right place for a closer look at what the current price might imply. The stock has returned 0.5% over the last 7 days and 20.2% over the last 30 days, but year to date it is sitting on a 16.7% decline and the 3 year and 5 year returns of 47.3% and 41.8% declines tell a different story to the 9.1% gain over the last year. Recent news coverage has focused on Bruker as part of longer term industry...
Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy costs.